1 Article title

- 2 COVID-19 vaccine uptake and associated risk factors among first antenatal care attendees in
- 3 Zambia, 2021-2022: a repeated cross-sectional study
- 5 **Short title**

4

7

- 6 COVID-19 vaccine uptake among pregnant women in Zambia
- 8 Authors' names
- 9 *Tannia Tembo^{1#a}, Paul Somwe^{1#b}, Samuel Bosomprah^{1#b,2}, Kalubi Kalenga^{1#c}, Nyembezi
- Moyo^{1#c}, Bupe Kabamba³, Victoria Seffren⁴, Sombo Fwoloshi⁵, Marie-Reine Rutagwera³, 10
- Maximillian Musunse³, Linos Mwiinga⁶, Julie R. Gutman⁴, Jonas Z. Hines^{6†}, Izukanji 11
- Sikazwe^{1†} 12
- 14 **Associated affiliations**
- 15 ^{1#a} Reproductive, maternal, newborn and child health (RMNCH), Center for Infectious Disease
- 16 Research in Zambia (CIDRZ), Lusaka, Zambia
- ^{1#b} Analysis Unit, Center for Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia 17
- 18 ^{1#c} Strategic Information Unit, Center for Infectious Disease Research in Zambia (CIDRZ),
- 19 Lusaka, Zambia
- ¹ Center for Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia 20
- 21 ² Department of Biostatistics, School of Public Health, University of Ghana, Accra
- 22 ³ PATH, Lusaka, Zambia
- 23 ⁴ Centers for Disease Control and Prevention, Atlanta, USA

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

⁵ University Teaching Hospital, Ministry of Health, Lusaka, Zambia ⁶ Centers for Disease Control and Prevention, Lusaka, Zambia *Corresponding author E-mail: Taniya. Tembo@cidrz.org; Tanniatembo@gmail.com (TT) † These authors contributed equally to this report. **Authors' contributions** Conceptualization was done by JG, JH, IS, and TT. They also provided oversight for the implementation of study activities. Data curation was done by TT, BK, KK, and M-RT. Data analysis was guided by SB and performed by PS. The initial draft was prepared by TT. All authors proofread and approved the final version of the manuscript. **Acknowledgments** The authors would like to acknowledge the Ministry of Health, Provincial Health Directors – Eastern and Lusaka provinces, District Health Directors – Chadiza, Chipata, Chongwe, and Lusaka Districts, and the National Health Research Authority for their collaboration at the preparatory stage of the study. We also wish to acknowledge the healthcare workers and community health workers (CHWs) at the health facilities for their participation and support during the implementation of study activities. Our special gratitude goes to the Research Assistants on the study - Beatrice Chibundi, Chikatizyo Mhango, Linda Phiri, and Patricia Z. Shabalu - for providing oversight for the implementation of study activities at each of the 39 health facilities.

Funding statement The "Assessing SARS-CoV-2 Seroprevalence during Routine Antenatal Care Visits in Zambia" was supported by the US Centers for Disease Control (CDC) under the terms of award number NU2GGH002251. Disclaimer The findings and conclusions in this paper are the products of study work implemented in Zambia and thus represent the opinions of the author(s). The paper does not necessarily represent the official position of the funding agency. **Competing interests** The authors declare that they have no competing interests.

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

ABSTRACT Introduction Pregnant women are considered a high-risk group for COVID-19, and a priority for vaccination. Routine antenatal (ANC) care provides an opportunity to track trends and factors associated with vaccine uptake. We sought to evaluate COVID-19 vaccine uptake among pregnant women attending ANC in Zambia. Methods We conducted a repeated cross-sectional study in 39 public health facilities in four districts in Zambia from September 2021 to September 2022. Pregnant women who were aged 15-49 years were enrolled during their first ANC visit. Every month, ~20 women per facility were interviewed during individual HIV testing and counseling. We estimated vaccine uptake as the proportion of eligible participants who self-reported having received the COVID-19 vaccine. **Results** A total of 9,203 pregnant women were screened, of which 9,111 (99%) were eligible and had vaccination status. Of the 9,111 included in the analysis, 1,818 (20%) had received the COVID-19 vaccine during the study period, with a trend of increasing coverage with time (0.5% in September 2020, 27% in September 2022). Conversely, 3,789 (42%) reported not being offered a COVID-19 vaccine. We found that older age, education, employment status, and prior COVID-19 infection were significantly associated with vaccine uptake.

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

Conclusion COVID-19 vaccine uptake among pregnant women was lower than estimates from the general population (27% across the four districts in September 2022), pointing to missed opportunities to protect this high-risk group. ANC visits were a viable point for conducting COVID-19 surveillance. Incorporating the vaccine as part of the routine ANC package might increase coverage in this group. Teaser key message Antenatal care clinics could be an easy and sustainable platform for increasing COVID-19 vaccine uptake among pregnant women. **Key Findings** Despite evidence that COVID-19 vaccines are safe in pregnancy, vaccine uptake was low among pregnant women in Zambia through the end of 2022. Various demographic characteristics were associated with the uptake of COVID-19 vaccines. **Key Implications** It is acceptable and feasible to assess COVID-19 vaccination uptake and hesitancy among pregnant women attending ANC. ANC may provide an easy, sustainable platform for routinely monitoring COVID-19 and other disease outbreaks. Key vaccination messages and mass vaccination strategies can be designed and adopted for pregnant women to reduce vaccine hesitancy and consequently, increase vaccine uptake.

COVID-19 vaccination could be incorporated into routine antenatal care to help increase vaccination coverage among pregnant women seeking antenatal care services.

INTRODUCTION

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

The coronavirus disease 19 (COVID-19) pandemic has presented unprecedented challenges globally, affecting all aspects of life, including the health of vulnerable populations. As of October 2023, there were approximately 771,151,224 confirmed cases of COVID-19 and 6,960,783 deaths, globally. ¹ Due to immunologic and physiologic changes, pregnant women are considered a highrisk group for COVID-19. ²⁻⁴ Those with SARS-CoV-2 infection are more susceptible to severe disease and mortality as compared to non-pregnant women. ^{5,6} Although COVID-19 vaccines are recommended for pregnant women to reduce the risk of severe COVID-19 disease and prevent adverse obstetric outcomes, vaccine hesitancy – a delay or refusal of safe vaccines – is reported to be higher among pregnant women than in the general population. ^{7,8} While survey results from Iran show that more than two-fifths of participants accepted receiving any vaccine, ⁹ fewer than one-third of pregnant women were interested in receiving the COVID-19 vaccine in Cameroon. 10 Understanding the factors influencing COVID-19 vaccine uptake among women attending antenatal care (ANC) is crucial for mitigating the impact of the virus on maternal and child health. Previous studies have shown variations in COVID-19 vaccine uptake among different populations, highlighting the influence of various factors such as age, education level, and socioeconomic status. 11–13 However, there is a limited understanding of these factors, particularly among pregnant women, who have distinct healthcare needs and considerations. Vaccination not only protects pregnant women from severe illness but also offers potential benefits to their unborn children through passive immunity. ^{14,15} By identifying risk factors and barriers to vaccine uptake, we can develop tailored interventions that address specific concerns and enhance vaccine acceptance. ultimately safeguarding the health and well-being of both expectant mothers and their babies. In

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

Zambia, COVID-19 vaccines were first made available in April 2021. The voluntary vaccination exercise initially targeted people above the age of 18 years and prioritized frontline health workers, people involved in the maintenance of core societal function, people with underlying conditions, and those in congregate settings. Despite initial uncertainties about the safety of COVID-19 vaccines in pregnancy, the Ministry of Health (MoH) updated guidelines in July 2021 to include vaccination for pregnant women. ¹⁶ Vaccine uptake among pregnant women in Zambia remains unknown as available evidence is based on results of vaccine acceptance among the general population. 17,18 This study aims to estimate COVID-19 vaccine uptake and associated risk factors among pregnant women attending their first antenatal care (ANC) visits at public health facilities in Chadiza, Chipata, Chongwe, and Lusaka districts of Zambia during the height of the third (Delta variant) and fourth (Omicron variant) waves. We also sought to assess the feasibility of using routine ANC to track trends and factors associated with the uptake of vaccines. This study contributes to a broader knowledge base on COVID-19 vaccination by focusing on specific population subsets, which can provide useful guidance on the development of targeted communication campaigns, healthcare policies, and interventions aimed at improving vaccine uptake and reducing disparities within this vulnerable group. **MATERIALS AND METHODS Study Design** We conducted repeated cross-sectional surveys on SARS-CoV-2 seroprevalence and vaccination coverage in pregnant women attending their first ANC visit in the maternal, newborn, and child

health (MNCH) clinics at 39 rural and urban public health facilities in four districts (Chadiza,

Chipata, Chongwe, and Lusaka). Participant recruitment was initiated on 4 September 2021 and was concluded on 30 September 2022 for study sites in Chipata, Chongwe and Lusaka districts. Initiation of participant enrolment was delayed at study sites in Chadiza and only started on 23 September 2021 and ended on 31 July 2022. In Zambia, the health system is classified into three categories: 1) community-level health posts and health centers; 2) Level 1-provincial and district hospitals and 3) Level 2-central-level specialized hospitals. ²³ Study sites (all public health facilities) were stratified according to location and selected using probability proportional to facility size based on each health facility's monthly mean number of pregnant women attending their first ANC visit based on historic monthly ANC attendance during the 2020 fiscal year. Study activities were incorporated into routine ANC services and leveraged infrastructure and human resources in the MNCH departments at public health facilities. In Chadiza district, study activities were incorporated into an ANC-based malaria surveillance pilot study. Health facility staff (CHWs, midwives, and phlebotomists and research assistants were trained in the study protocol, laboratory procedures, and human subject protection. Additional methodological details of the study are described elsewhere. ¹⁹ This analysis looks at interview data on COVID-19 vaccination from the broader study.

Recruitment and Enrollment of Study Participants

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

A CHW provided information on the ANC COVID-19 surveillance study during sensitization meetings in the community and group counseling sessions at the health facility. Once every week, on a day that each health facility provided routine ANC services for first-time attendees, CHWs conveniently identified pregnant women and screened them for eligibility to participate in the study. Pregnant women who were aged 15-49 years, confirmed to be pregnant, registered as a first

ANC attendee, and provided consent, were enrolled in the study. Potential participants were screened for active SARS-CoV-2 infection using a paper-based checklist of symptoms. Those who showed one or more symptoms were excluded and referred to a SARS-CoV-2 testing center to be managed according to national guidelines if they had a positive test result. At each study site, trained midwives shared an information sheet with eligible participants and obtained consent from up to 20 pregnant women per month, cumulatively enrolling 200 pregnant women per district.

Data Collection and Management

At the time of providing routine ANC tasks such as performing physical examinations, administering antimalaria prophylaxis, prescribing prenatal vitamins and drawing blood samples for routine HIV and syphilis testing, a midwife administered an electronic questionnaire to consented participants. The study questionnaire was designed in Open Data Kit (ODK) – a free, open-source suite of software tools that facilitates the collection, management and use of data using portable mobile devices with Internet connectivity. ²⁴ To ensure confidentiality and privacy, a unique identification number was assigned to individual participants during data collection. The questionnaire was uploaded onto a tablet which was handled by trained midwives and research assistants.

To estimate COVID-19 vaccine uptake and associated risk factors among pregnant women attending their first antenatal care, the study collected participants' vaccination status, sociodemographic characteristics, self-reported past SARS-CoV-2 infection, and exposure. SARS-CoV-2 preventive measures and behavior such as the proper wearing of masks were observed and captured in the questionnaire. In addition, the study determined the acceptability and feasibility of

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

monitoring COVID-19 vaccination uptake and hesitancy among pregnant women attending ANC. Acceptability was defined as a multi-faceted construct that reflects the extent to which the healthcare providers and pregnant women enrolled in the study considered the SARS-CoV-2 surveillance to be appropriate and was measured by its perceived effectiveness – the extent to which the SARS-CoV-2 surveillance was perceived as likely to achieve its purpose. ²⁰ Feasibility was defined as the study's appropriateness for further testing to determine relevance and sustainability 21 and was measured by recruitment rates, length of time from initiation to completion of the targeted number of participants, and number of eligible participants required to recruit sample size. Initially, participants were asked only if they had been vaccinated or not. The questionnaire was updated in May 2021 to gather information about whether the participants had been offered a vaccine in addition to whether they had accepted it, and for those who were unvaccinated, additional information was collected about the reasons for not being vaccinated. Overall, 3,655 participants were recruited before the updated questionnaire was implemented, meaning they only had a binary vaccination status collected. COVID-19 vaccination status was self-reported, although study staff attempted to verify information from vaccination cards if participants had them available on the day of their ANC visit. Data were reviewed on a scheduled basis and missing variables were communicated to health facility staff and research assistants to attempt follow-up and completion. All completed questionnaires were uploaded onto a central server individually or batched. Other data were documented in study-specific logs and registers. Additionally, COVID-19 vaccine coverage data

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

in the general population in the four implementation districts were obtained from the Zambia MoH so that a comparison could be made to the estimates from this study. General population vaccination data were extracted from the national District Health Information System (DHIS) 2-COVAX tracker – a global digital health data toolkit that facilitated the capture of individual-level COVID-19 data of investigated cases; including vaccination status. ²² **Statistical Analysis** A sample size of 200 women per district per month was selected based on estimating an acceptable margin of error for varying SARS-CoV-2 seroprevalences that were expected to vary by location and enrollment month (this sample size would produce a 95% confidence interval [CI] half-width of 2.4% at the lowest expected seroprevalence of 3%). The sample size was adjusted to account for a design effect of 1.5. Background characteristics were summarized using frequency and proportions for categorical variables, and median and interquartile range for continuous variables. We estimated the prevalence of COVID-19 uptake as the proportion of pregnant women who received (i.e., reported or verified by vaccination card) COVID-19 vaccine. The corresponding 95% CIs were adjusted for the clustering of participants within a health facility. We used a mixed-effect logistic regression model to identify factors independently associated with uptake. To allow for variation in the secular trend across clusters (i.e., health facilities), we extended the random-effects components to allow a random interaction between time and health facilities (i.e., we generated a new variable by combining two dimensions of health facilities and time). P-values less than 0.05 were considered statistically significant. All statistical analyses were performed using Stata 18 MP (StataCorp, College Station, TX, USA).

Ethics Considerations

This study was reviewed and approved by the National Health Research Authority (NHRA), a statutory body under the Zambian MoH, and following the US Centers for Disease Control and Prevention (CDC) human research protection procedures as the CDC investigators were not engaged (i.e., did not interact with human subjects or have access to identifiable data or specimens for research purposes). It was also reviewed and approved, particularly for the Chadiza sites, by the University of Zambia Biomedical Research Ethics Committee (UNZABREC) and PATH's Research Ethics Committee (PATH REC). Information sheets for participants were developed and translated into two local languages. Individual written consent and assent were obtained from adults and minors aged below 18 years, respectively, in a language of their choice and a copy of an information sheet was offered to the participant after consenting. Assent was obtained from minors only after consent was given by their parent(s) or guardian(s). Illiterate adults were required to provide consent in the presence of an impartial witness.

RESULTS

Study Enrollment Cascade

During the study period, a total of 9,203 pregnant women were approached to participate in the study. Of these, 19 (0.2%) were ineligible due to their age and were excluded (Figure 1). A further 73 did not have vaccination status, giving a total of 9,111 included in the analysis. Overall, 1,818 (20.0%) pregnant women were vaccinated against COVID-19 by the time of their first ANC visit and, of 7,293 unvaccinated women, 5,456 had additional vaccination information collected (i.e.,

were administered the updated questionnaire). At least 1,667 (30.6%) had been offered a vaccine but refused (Figure 1) and provided reasons for refusal (Figure 3).

Figure 1: Flow chart of participant recruitment

300

301

302


303

306

307

308

309



Background Characteristics and COVID-19 Uptake

The median age of participants was 24 years (interquartile range [IQR]: 20-30) and over half (4,944 [54.3%]) of participants were aged between 20-29 years (Table 1). Half of the participants (4,557) had attained some or completed primary school education while half were employed either

formally or informally. Almost all, (8,917 [95%]) participants had never tested for COVID-19 before their ANC visit (Table 1). An estimated 4% of pregnant women reported ever being in contact with a COVID-19-infected individual, either within and/or outside their household. Proper use of masks was observed in only 3,492 (38.3%) of the participants. Seven hundred ninety-one (8.7%) of the pregnant women either tested positive for HIV or had a known positive HIV status on the day of their visit. Of the 9,111 participants with a vaccination status, 1,818 (20%) reported having received a COVID-19 vaccine while 3,789 (41.6%) of women said they had never been offered a vaccine (Figure 1).

Table 1. COVID-19 vaccine uptake among pregnant women attending first ANC visit by socio-demographic characteristics, N=9111

Table 1. Background characteristics and COVID-19 vaccine uptake among pregnant women attending first ANC visit

Total number
of women
N (% of total)
9111 (100%)
1915 (21.0)
2379 (26.1)
2494 (27.4)
2323 (25.5)

Age group	
Median (IQR)	24 (20-30)
15-19	1736 (19.1)
20-29	4944 (54.3)
30-39	2003 (22.0)
40-49	232 (2.5)
Missing	196 (2.2)
Education level	
Some or completed secondary education	3783 (41.5)
Some or completed primary education	4557 (50.0)
No education	771 (8.5)
Employment status	
Employed	4574 (50.2)
Unemployed	4092 (44.9)
Other	445 (4.9)
Ever tested positive for COVID-19	
No	8917 (97.9)
Household contact positive for COVID-19	
No	8800 (96.6)
Contact with anyone with COVID-19	
No	8590 (94.3)
Mask wearing frequency	

Everytime or most of the time	3553 (39.0)
About half the time	1009 (11.1)
Rarely	1910 (21.0)
Never	549 (6.0)
Missing	2090 (22.9)
Currently wearing mask†	_
Mask present and properly worn	3492 (38.3)
Mask present but not properly worn	2118 (23.2)
No mask	1411 (15.5)
Missing	2090 (22.9)
HIV status	
Negative	8026 (88.1)
1. Observations missing vaccine status were excluded, N=73 (0.8%)	
†	

Factors independently associated with vaccine uptake

In a multivariable mixed-effects logistic regression model, we found that age group, education, employment status, ever testing positive for COVID-19, and HIV infection were all significantly associated with COVID-19 vaccine uptake (Table 2). Increasing age was associated with increased COVID-19 vaccination uptake. We observed a lower proportion of COVID-19 vaccination among pregnant women who had no education ((aPR): 0.79, 95% CI: 0.62-1.00; P = 0.007) or had attained some or completed primary education (aPR): 0.86 95%CI: 0.75-0.97; P = 0.001) as compared to those who had some or completed secondary education. Unemployed pregnant women had lower

vaccination prevalence ((aPR): 0.69, 95% CI: 0.58-0.82; P = <0.001) as compared to pregnant women who were employed. Additionally, pregnant women who had ever tested positive for COVID-19 had 1.70 times (95% CI: 1.31-2.21; P = <0.001) greater likelihood of receiving a vaccine compared to those who had not tested positive for COVID-19 in the past. Similarly, pregnant living with HIV were 1.18 times (95% CI:1.02-1.37; P = 0.026) more likely to be vaccinated compared to those who were not infected with HIV.

Table 2. Factors associated with vaccine coverage among pregnant women attending first ANC visit, n=8,750

Characteristics	Total number of women	COVID- 19 vaccine uptake n (row		Crude PR (95% CI)		Overall P-value	Adjusted PR (95% CI)		Overall P-value
	N	%)	95% CI		P-value			P-value	
Age group									
	1736		12.8-	0.72 (0.62-			0.78 (0.66-		
15-19		275 (15.8)	19.5	0.84)	***<0.001		0.92)	***<0.001	
	4944		15.7-						
20-29		989 (20.0)	25.1	1		0.004	1		0.010
	2003		17.7-	1.12 (1.01-		< 0.001	1.06 (0.94-		0.019
30-39		467 (23.3)	30.1	1.25)	**0.028		1.18)	0.346	
	232		17.4-	1.11 (0.86-			1.03 (0.81-		
40-49		56 (24.1)	32.4	1.42)	0.419		1.31)	0.797	
Education level									•

Some or completed	3783												
secondary education		796 (21.0)	16-27.2	1			1						
Some or completed	4557		14.5-	0.85 (0.75-		< 0.001	0.86 (0.75-		0.014				
primary education		855 (18.8)	23.9	0.96)	***0.009	<0.001	\0.001	\0.001	\0.001	\0.001	0.97)	***0.001	0.014
	771		14.4-	0.87 (0.71-			0.79 (0.62-						
No education		167 (21.7)	31.3	1.06)	0.171		1.00)	***0.007					
Employment status						•							
	4574	1130	19.8-										
Employed		(24.7)	30.4	1			1						
	4092		10.5-	0.65 (0.56-		< 0.001	0.69 (0.58-		< 0.001				
Unemployed		589 (14.4)	19.4	0.76)	***<0.001	<0.001	0.82)	***<0.001	<0.001				
	445		14.4-	0.85 (0.71-			0.88 (0.74-						
Other		99 (22.2)	32.7	1.02)	*0.076		1.05)	0.127					
Ever tested positive													
for COVID-19													

	8917	1725	15.4-						
No		(19.3)	23.9	1		<0.001	1		رم مرم ا
	194		38.5-	2.01 (1.50-			1.70 (1.31-		< 0.001
Yes		93 (47.9)	57.5	2.70)	***<0.001		2.21)	***<0.001	
Household contact						•			
positive for COVID-									
19									
	8800	1725	15.6-						
No		(19.6)	24.3	1		< 0.001			
	301		20.9-	1.46 (1.11-		<0.001			
Yes		91 (30.2)	41.5	1.94)	***0.007				
Contact with anyone						•			
with COVID-19									
	8590	1639	15.1-			<0.001			
No		(19.1)	23.8	1		<0.001			

	357		20.2-	1.47 (1.11-		
Yes		106 (29.7)	41.3	1.97)	***0.008	
Mask wearing						•
frequency						
Everytime or most	3553		17.8-			
of the time		834 (23.5)	30.3	1		
	1009		20.8-	0.96 (0.81-		
About half the time		282 (27.9)	36.5	1.12)	0.583	< 0.001
	1910		17.5-	0.71 (0.57-		<0.001
Rarely		437 (22.9)	29.3	0.88)	***0.002	
	549			0.80 (0.64-		
Never		142 (25.9)	18-35.6	1.00)	**0.046	
Currently wearing						
mask						
Mask present and	3492		20.8-			<0.001
properly worn		933 (26.7)	33.6	1		< 0.001

Mask present but	2118		14.3-	0.71 (0.59-					
not properly worn		402 (19.0)	24.7	0.85)	***<0.001				
	1411		20.5-	0.83 (0.71-					
No mask		360 (25.5)	31.3	0.97)	**0.022				
HIV status						•			•
	8026	1617							
Negative		(20.1)	16-25	1		< 0.001	1		0.028
	791		17.9-	1.27 (1.12-		\0.001	1.18 (1.02-		0.028
Positive		174 (22.0)	26.8	1.45)	***<0.001		1.37)	**0.026	

Vaccine uptake over time

Overall, COVID-19 vaccination uptake among pregnant women was at 0.5% at the beginning of the study in September 2021 and had increased to 27% by September 2022 (Figure 2). When compared by district, uptake varied between 2.8% and 17.4% in September 2021 and 21.8% to 29% in September 2022. Throughout implementation, a steady increase in vaccine uptake was observed among participants in Chadiza (Figure 2). COVID-19 vaccine coverage among women at first ANC visits was lower than coverage in the general population in these districts (Figure 2).

Figure 2: Vaccine uptake among pregnant women by facility (September 2021 to September 2022, N=9,111)






Figure 2. COVID-19 vaccine coverage estimates in pregnant women attending first ANC visit compared with estimates in the general population



Reasons for not taking the COVID-19 vaccine if offered

Of the 3,789 pregnant women who reported never having been offered a vaccine, 1,338 (35.3%) said that they would not take a COVID-19 vaccine even if they were offered and provided reasons for refusal (Figure 3). Pregnancy safety concerns and vaccine effects were the most common reasons for refusing to take the vaccine (462 [35%] and 374 [28%], respectively). An additional 250 (19%) would not take it because of uncertainties surrounding its safety, and 244 (18%) of the participants would not take a vaccine because they did not have sufficient information on the vaccine. The least cited reasons for refusal to take a COVID-19 vaccine were religious concerns and the need to seek permission from a partner or family (9% and 8%, respectively).

Figure 3: reasons for not taking vaccine if offered, n=1,338



DISCUSSION

Most pregnant women in the four districts of Zambia were not vaccinated against COVID-19, despite being at high risk for severe outcomes. Vaccination coverage increased over the study period and was higher in all four districts compared to contemporaneous coverage estimates of the general population. Despite evidence that COVID-19 vaccines are safe in pregnancy, only ten of the 54 African countries were recommending COVID-19 vaccines for pregnant women as of February 2022. ²³ In Zambia, COVID-19 vaccines were first made available for the general

population in April 2021 24 but, vaccine coverage remains well below the World Health

Organization's (WHO) target to vaccinate 70% of the world's population by mid-2022. ²⁵ Given

initial uncertainty about vaccine safety in pregnancy, the MoH delayed recommending COVID-

19 vaccination for pregnant women until July 2021, which might have contributed to vaccine

hestitancy in this group. Our findings correlate with a study conducted in Ethiopia in which only

14.4% of the participants had received at least one dose of COVID-19 vaccines by March 2022. ²⁶

Similarly, vaccine uptake in Cameroon was low (31%) but, uptake did not differ between the

pregnant and general population. ²⁷

Low vaccination rates in low-and-middle-income (LMICs) African countries are partly due to the

inequitable distribution of vaccines caused by constrained financial resources to support competing

priorities in underdeveloped health systems and bottlenecks in the supply chain which may lead to

delayed vaccine rollout. ^{28,29} Studies have also reported that pregnant women did not receive

COVID-19 vaccines due to their limited availability in Africa, perhaps an indication of the inability

of pharmaceutical companies to manufacture vaccines in Africa, and the compromised quality of

the vaccines manufactured by international pharmaceutical companies for the African market. ^{27,30}

COVID-19 vaccination uptake is also hampered by the low-risk perception of the pandemic,

concern about adverse vaccine effects, low vaccination awareness, and low acceptance, intention

and willingness to get vaccinated. 31,32

COVID-19 vaccine hesitancy occurs against a backdrop of social-cultural complexities, poor

government response in demystifying social and traditional myths and theories, and poor

community involvement in public health measures. ³³ Pregnant women in our study reported not

having adequate information about the COVID-19 vaccine and were therefore concerned about

the side effects of the vaccine on their pregnancy, vaccine safety, and efficacy, findings which

were similar to an earlier study by Dinga et al. 34 In our study, religious affiliation was not

associated with vaccine hesitancy, and neither was the need to seek permission for vaccination

from a family member or partner.

Most unvaccinated pregnant women recruited into this study were willing to accept a COVID-19

vaccine if it were offered to them. However, they reported that a vaccine had not been offered to

them, potentially pointing to insufficient effectiveness of mass media campaigns (which were

widespread during this period in Zambia) and individual outreach during routine health care visits

in demand creation. Pregnant women who expressed willingness to receive a vaccine on the day

of their first ANC visit were referred to a designated center to receive a vaccine even though their

intake was not documented by the study.

Several factors associated with low vaccine uptake were identified, including; age group,

educational level, and HIV infection. In studies from other African countries, COVID-19

vaccination uptake has varied across age groups. ^{32,35,36} In our study, older pregnant women were

more likely to have received a COVID-19 vaccine compared to younger women. This increase in

uptake could be attributed to the government targeting older persons for receipt of the vaccine or

increased understanding of risks and their prevailing knowledge of how the COVID-19 disease

impacts older people given their own advancing age. ²⁶ COVID-19 risk perception and behavior

can be influenced by a higher level of education among populations. ³⁷ While some studies have

not observed any associations between educational level and COVID-19 vaccine uptake, ³⁸ our

findings contradict those found in Ethiopia where vaccine uptake was lower among participants

who had a higher level of education and had attended college or university possibly due to their

increased access to information and awareness of the potential side effects and safety. ^{26,39}

Risk perception is a critical factor in vaccine decisions. ⁴⁰ In this study, pregnant women who were

not employed were less likely to receive a COVID-19 vaccine compared to those who were

engaged in formal and informal work. This reduced uptake among the unemployed could be

attributed to their perceived lowered risk of infection as they had limited contact with individuals

outside of their household, particularly when lockdown regulations were strictly enforced.

Additionally, a history of ever testing positive for COVID-19 influenced pregnant women's

decision to get a COVID-19 vaccine. These results corroborate with findings from studies in

Indonesia and the UK which found that a higher perceived risk of COVID-19 infection was

associated with higher acceptance of the vaccine. 41-43 Moreover, in Indonesia and the UK,

receiving the vaccine was perceived to be vital for protecting oneself and preventing disease

transmission.

Similarly, a higher proportion of pregnant women who had contact with a known or suspected

COVID-19 patient within or outside their household were more likely to receive a COVID-19

vaccine. However, a majority of the pregnant women in this study indicated that they did not know

about being in contact with a positive COVID-19 case. This could be because many cases of

COVID-19 are asymptomatic or that symptoms are mild and nonspecific, and people did not get

tested, or due to the limited availability of COVID-19 testing in Zambia. A household study in six

districts in Zambia during the first wave estimated about one confirmed COVID-19 case for every

92 infections, ⁴⁴, and in this study there continued to be substantial case ascertainment gaps. ⁴⁵

COVID-19 vaccine hesitancy has been investigated among people living with HIV (PLWHIV). In

Zambia, the MOH targeted PLHIV for COVID-19 vaccinations given their elevated risk of severe

disease and substantial investments and achievements in HIV care in the country. ⁴⁶ In our study,

we assessed vaccine hesitancy among HIV-infected pregnant women and found a high degree of

COVID-19 vaccine uptake among HIV-infected pregnant women as compared to those who were

not infected with HIV. These results suggest high levels of vaccine acceptability and accessibility

among pregnant women living with HIV. 47 Our results are similar to those reported in Nigeria

where one in five women living with and at risk of HIV had a lower likelihood of being vaccine-

hesitant. 48

For this study, data collected over 13 months shows that there was a modest increase in vaccination

uptake among study participants from 0.4% at the beginning of the study in September 2021 to

2.6% at the end of the study in September 2022. This is in contrast to results from a meta-analysis

that showed a higher rise in pooled COVID-19 vaccine acceptance rates in Ethiopia from 14.1%

in 2022 to 42.46% in 2023. ^{26,49} Of note is that in this study, a proportion of the pregnant women

who reported receiving a vaccine may have been vaccinated before they conceived. The gradual

increase in the proportion of vaccinated pregnant women in our study could be attributed to an

increase in the number of vaccine doses received by the MoH over time and their embarking on

an ambitious 10-day COVID-19 vaccination campaign to reach the 70% eligible population in

26

May 2022. 50

Strengths and limitations of the study

A major strength of this study was the leveraging of infrastructure and human resources in the MNCH departments at public health facilities to enroll pregnant women seeking routine ANC services. ⁵¹ Health care providers and community-based volunteers, who were already providing ANC services at the study sites were engaged to assist with carrying out study procedures thereby easing the study implementation process, reducing costs, and gaining the confidence of participants. The study was able to access a longitudinal selection of pregnant women over time and triangulate a limited amount of routine data collected from part of the national DHIS2-COVAX tracker with data collected from study participants from participants to validate the findings. A limitation of the study is that the analysis does not include vaccine data of almost 1,837 participants as they were recruited into the study before the vaccine follow-up questions were appended to the questionnaire. Additionally, the districts were purposefully selected so the findings might not be generalizable to all of Zambia.

CONCLUSION

Using pregnant women seeking routine antenatal care in public health facilities to assess COVID-19 vaccination status, uptake over time, intent, and acceptance of vaccine is acceptable and feasible in a low-resource setting. Overall, this study found a low uptake of COVID-19 vaccines among pregnant women attending first ANC in rural and urban settings, indicating a need to reinforce vaccine uptake efforts to prevent severe disease and adverse outcomes among these vulnerable populations. The leveraging of existing infrastructure and human resources provided an easy, sustainable platform for routinely monitoring COVID-19 vaccine, and consequently helped to

understand vaccine hesitancy among pregnant women. This is critical for devising key vaccination messages and can facilitate the design and adoption of mass vaccination strategies for minority groups, reduce vaccine hesitancy, and subsequently increase vaccine uptake. Demand generation for vaccines might be more effective if done during routine health services and targeted at individuals (i.e., inviting pregnant women to get vaccinated). This would be possible by incorporating the vaccine as part of the routine ANC package to increase coverage among pregnant women.

REFERENCES

- World Health Organization. WHO Coronavirus (COVID-19) Dashboard. Global Situation.
 Published July 12, 2023. Accessed July 13, 2023. https://covid19.who.int/
- Kolb JJ, Radin JM, Quer G, Rose AH, Pandit JA, Wiedermann M. Prevalence of Positive COVID-19 Test Results Collected by Digital Self-report in the US and Germany. *JAMA Netw Open*. 2023;6(1):e2253800. doi:10.1001/jamanetworkopen.2022.53800
- 3. Khan S, Siddique R, Bai Q, et al. Coronaviruses disease 2019 (COVID-19): Causative agent, mental health concerns, and potential management options. *Journal of Infection and Public Health*. 2020;13(12):1840-1844. doi:10.1016/j.jiph.2020.07.010
- 4. Sh. Nur MA, Dahie HA, Hassan NA, et al. Seroprevalence of SARS-CoV-2 virus antibodies and sociodemographic features of pregnant women in Mogadishu, Somalia: a cross-sectional survey study. *BMJ Open.* 2022;12(6):e059617. doi:10.1136/bmjopen-2021-059617

- Centers for Disease Control and Prevention. COVID Data Tracker. US Department of Health and Human Services; 2023. Accessed May 7, 2023. ttps://COVID.cdc.gov/COVID-datatracker/#datatracker-home
- 6. Dehingia N, Raj A. Sex differences in COVID-19 case fatality: do we know enough? *The Lancet Global Health*. 2021;9(1):e14-e15. doi:10.1016/S2214-109X(20)30464-2
- 7. Galanis P, Vraka I, Siskou O, Konstantakopoulou O, Katsiroumpa A, Kaitelidou D. Uptake of COVID-19 Vaccines among Pregnant Women: A Systematic Review and Meta-Analysis. *Vaccines (Basel)*. 2022;10(5):766. doi:10.3390/vaccines10050766
- MacDonald NE, SAGE Working Group on Vaccine Hesitancy. Vaccine hesitancy: Definition, scope and determinants. *Vaccine*. 2015;33(34):4161-4164. doi:10.1016/j.vaccine.2015.04.036
- 9. Firouzbakht M, Sharif Nia H, Kazeminavaei F, Rashidian P. Hesitancy about COVID-19 vaccination among pregnant women: a cross-sectional study based on the health belief model. *BMC Pregnancy Childbirth*. 2022;22(1):611. doi:10.1186/s12884-022-04941-3
- Gunawardhana N, Baecher K, Boutwell A, et al. COVID-19 vaccine acceptance and perceived risk among pregnant and non-pregnant adults in Cameroon, Africa. Sallam M, ed. *PLoS ONE*. 2022;17(9):e0274541. doi:10.1371/journal.pone.0274541
- 11. Lee J, Huang Y. COVID-19 Vaccine Hesitancy: The Role of Socioeconomic Factors and Spatial Effects. *Vaccines*. 2022;10(3):352. doi:10.3390/vaccines10030352

- 12. Larsson L, Dziva Chikwari C, Simms V, et al. Addressing sociodemographic disparities in COVID-19 vaccine uptake among youth in Zimbabwe. *BMJ Glob Health*. 2023;8(7):e012268. doi:10.1136/bmjgh-2023-012268
- Adedeji-Adenola H, Olugbake OA, Adeosun SA. Factors influencing COVID-19 vaccine uptake among adults in Nigeria. Yunusa I, ed. *PLoS ONE*. 2022;17(2):e0264371. doi:10.1371/journal.pone.0264371
- 14. Centre for Disease Control and Prevention. Pregnancy or Breastfeeding. Pregnancy and Breastfeeding: What You Need to Know. Published July 2023.
 https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/pregnancy.html#:~:text=Antibodies%20made%20after%20 pregnant%20people,the%20mother%20to%20her%20baby.
- Lamptey E, Senkyire EK, Banoya MT, Yaidoo S. COVID-19 vaccination in pregnancy: A review of maternal and infant benefits. *Gynecology and Obstetrics Clinical Medicine*.
 2022;2(3):124-128. doi:10.1016/j.gocm.2022.07.003
- 16. Ministry of Health. STATEMENT ON COVID-19 IN ZAMBIA LUSAKA. Facebook.
 Published July 6, 2021. Accessed November 8, 2023.
 https://www.facebook.com/mohzambia/photos/a.773733439467982/1949793125195335/?ty
 pe=3
- 17. Knight M, Bunch K, Vousden N, et al. Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population based cohort study. *BMJ*. Published online June 8, 2020:m2107. doi:10.1136/bmj.m2107

- 18. Jafari M, Pormohammad A, Sheikh Neshin SA, et al. Clinical characteristics and outcomes of pregnant women with COVID-19 and comparison with control patients: A systematic review and meta-analysis. *Rev Med Virol*. 2021;31(5):1-16. doi:10.1002/rmv.2208
- 19. Heilmann E, Tembo T, Chilambe F, et al. SARS-CoV-2 Serprevalence Trend among Pregnant Women in Zambia, 2021-2022. Presented at: Conference on Retroviruses and Opportunistic Infections; February 2023; Denver, Colarado. Accessed August 9, 2023. https://www.croiconference.org/abstract/sars-cov-2-seroprevalence-trend-among-pregnant-women-in-zambia-2021-2022/
- 20. Sekhon M, Cartwright M, Francis JJ. Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework. *BMC Health Serv Res*. 2017;17(1):88. doi:10.1186/s12913-017-2031-8
- 21. Bowen DJ, Kreuter M, Spring B, et al. How We Design Feasibility Studies. *American Journal of Preventive Medicine*. 2009;36(5):452-457. doi:10.1016/j.amepre.2009.02.002
- 22. DHIS2. DHIS2 COVID-19 Vaccine Delivery Toolkit Strengthen national immunization systems, introduce fit-for-purpose digital solutions and leverage local expertise for equitable COVID-19 vaccine delivery. Published November 7, 2023. Accessed November 7, 2023. https://dhis2.org/covid-vaccine-delivery/
- 23. Joi P. COVID-19 greatly increases risks to pregnant women: largest sub-Saharan study.

 GAVI: The Vaciene Alliance. Published June 9, 2022. Accessed June 28, 2023.

 https://www.gavi.org/vaccineswork/covid-19-greatly-increases-risks-pregnant-women-largest-sub-saharan-study

- 24. World Health Organization. Zambia launches the COVID-19 vaccination. World Health Organization. Published April 16, 2021. https://www.afro.who.int/news/zambia-launches-covid-19-vaccination
- 25. World Health Organization. WHO Policy Brief: Reaching COVID-19 Vaccination Targets.
 WHO; 2022. Accessed June 28, 2023. https://www.who.int/publications/m/item/strategy-to-achieve-global-covid-19-vaccination-bymid-2022.
 2.
- 26. Chekol Abebe E, Ayalew Tiruneh G, Asmare Adela G, et al. COVID-19 vaccine uptake and associated factors among pregnant women attending antenatal care in Debre Tabor public health institutions: A cross-sectional study. *Front Public Health*. 2022;10:919494. doi:10.3389/fpubh.2022.919494
- 27. Gunawardhana N, Baecher K, Boutwell A, et al. COVID-19 vaccine acceptance and perceived risk among pregnant and non-pregnant adults in Cameroon, Africa. Sallam M, ed. *PLoS ONE*. 2022;17(9):e0274541. doi:10.1371/journal.pone.0274541
- 28. Banerjee D, Mukhopadhyay S, Sahana Asmeen M, Javed A. COVID-19 Vaccination: crucial roles and opportunities for the mental health professionals. *Glob Ment Health*. 2021;8:e25. doi:10.1017/gmh.2021.25
- Duroseau B, Kipshidze N, Limaye RJ. The impact of delayed access to COVID-19 vaccines in low- and lower-middle-income countries. *Front Public Health*. 2023;10:1087138. doi:10.3389/fpubh.2022.1087138
- 30. Makoni M. The quest for more COVID-19 vaccinations in Africa. *The Lancet Respiratory Medicine*. 2022;10(7):e70-e71. doi:10.1016/S2213-2600(22)00193-X

- 31. Lawal L, Aminu Bello M, Murwira T, et al. Low coverage of COVID-19 vaccines in Africa: current evidence and the way forward. *Human Vaccines & Immunotherapeutics*. 2022;18(1):2034457. doi:10.1080/21645515.2022.2034457
- 32. Gudayu TW, Mengistie HT. COVID-19 vaccine acceptance in sub-Saharan African countries: A systematic review and meta-analysis. *Heliyon*. 2023;9(2):e13037. doi:10.1016/j.heliyon.2023.e13037
- 33. Ochola EA. Vaccine Hesitancy in Sub-Saharan Africa in the Context of COVID-19 Vaccination Exercise: A Systematic Review. *Diseases*. 2023;11(1):32. doi:10.3390/diseases11010032
- 34. Dinga JN, Sinda LK, Titanji VPK. Assessment of Vaccine Hesitancy to a COVID-19

 Vaccine in Cameroonian Adults and Its Global Implication. *Vaccines (Basel)*. 2021;9(2):175.

 doi:10.3390/vaccines9020175
- 35. Worede DT, Kassahun M, Endalew B. COVID-19 vaccine acceptance and predictors among pregnant women in Ethiopia: Systematic Review and Meta-Analysis. *Public Health in Practice*. 2023;5:100386. doi:10.1016/j.puhip.2023.100386
- 36. Hoque AM, Buckus S, Hoque M, Hoque ME, Van Hal G. COVID-19 Vaccine Acceptability Among Pregnant Women at a Primary Health Care Facility in Durban, South Africa. *EJMED*. 2020;2(5). doi:10.24018/ejmed.2020.2.5.493
- 37. Zhang R, Wang C. Risk perception of COVID-19 and its related factors among centralized medical isolation groups in China. *Front Psychol.* 2023;14:1131076. doi:10.3389/fpsyg.2023.1131076

- 38. Rikitu Terefa D, Shama AT, Feyisa BR, et al. COVID-19 Vaccine Uptake and Associated Factors Among Health Professionals in Ethiopia. *IDR*. 2021;Volume 14:5531-5541. doi:10.2147/IDR.S344647
- 39. Al-Marshoudi S, Al-Balushi H, Al-Wahaibi A, et al. Knowledge, Attitudes, and Practices (KAP) toward the COVID-19 Vaccine in Oman: A Pre-Campaign Cross-Sectional Study. *Vaccines*. 2021;9(6):602. doi:10.3390/vaccines9060602
- 40. Kamal AHM, Sarkar T, Khan MM, et al. Factors Affecting Willingness to Receive COVID-19 Vaccine Among Adults: A Cross-sectional Study in Bangladesh. *Journal of Health Management*. Published online October 14, 2021:097359842110506. doi:10.1177/09735984211050691
- 41. Harapan H, Wagner AL, Yufika A, et al. Acceptance of a COVID-19 Vaccine in Southeast Asia: A Cross-Sectional Study in Indonesia. *Front Public Health*. 2020;8:381. doi:10.3389/fpubh.2020.00381
- 42. Sherman SM, Smith LE, Sim J, et al. COVID-19 vaccination intention in the UK: results from the COVID-19 vaccination acceptability study (CoVAccS), a nationally representative cross-sectional survey. *Human Vaccines & Immunotherapeutics*. 2021;17(6):1612-1621. doi:10.1080/21645515.2020.1846397
- 43. Cerda AA, García LY. Hesitation and Refusal Factors in Individuals' Decision-Making Processes Regarding a Coronavirus Disease 2019 Vaccination. *Front Public Health*. 2021;9:626852. doi:10.3389/fpubh.2021.626852

- 44. Mulenga LB, Hines JZ, Fwoloshi S, et al. Prevalence of SARS-CoV-2 in six districts in Zambia in July, 2020: a cross-sectional cluster sample survey. *The Lancet Global Health*. 2021;9(6):e773-e781. doi:10.1016/S2214-109X(21)00053-X
- 45. Heilmann E, Tembo T, Fwoloshi S, et al. Trends in SARS-CoV-2 seroprevalence among pregnant women attending first antenatal care visits in Zambia: a repeated cross-sectional survey, 2021-2022. *The Lancet Global Health*.
- 46. Bobo P, Hines JZ, Chilengi R, et al. Leveraging HIV Program and Civil Society to Accelerate COVID-19 Vaccine Uptake, Zambia. *Emerg Infect Dis.* 2022;28(13). doi:10.3201/eid2813.220743
- 47. Muhindo R, Okoboi S, Kiragga A, King R, Arinaitwe WJ, Castelnuovo B. COVID-19 vaccine acceptability, and uptake among people living with HIV in Uganda. Amuzie CII, ed. *PLoS ONE*. 2022;17(12):e0278692. doi:10.1371/journal.pone.0278692
- 48. Folayan MO, Arije O, Enemo A, et al. Associations between COVID-19 vaccine hesitancy and the experience of violence among women and girls living with and at risk of HIV in Nigeria. *African Journal of AIDS Research*. 2022;21(4):306-316. doi:10.2989/16085906.2022.2118615
- 49. Worede DT, Kassahun M, Endalew B. COVID-19 vaccine acceptance and predictors among pregnant women in Ethiopia: Systematic Review and Meta-Analysis. *Public Health in Practice*. 2023;5:100386. doi:10.1016/j.puhip.2023.100386

- 50. Ministry of Health. Nationwide 10-day COVID-19 Campaign. Nationwide 10-day COVID-19 Campaign. Published May 18, 2022. Accessed July 13, 2023. https://twitter.com/mohzambia/status/1527013308305391619?lang=en
- 51. Tembo T, Heilmann E, Kabamba BM, et al. Implementing SARS-CoV-2 Routine Surveillance in Antenatal Care in Zambia: Best Practices and Lessons Learned. Published online 2023.